[go: up one dir, main page]

HK1112588A1 - Extending time to disease progression or survival in cancer patients using a her dimerization inhibitor - Google Patents

Extending time to disease progression or survival in cancer patients using a her dimerization inhibitor Download PDF

Info

Publication number
HK1112588A1
HK1112588A1 HK08108174.3A HK08108174A HK1112588A1 HK 1112588 A1 HK1112588 A1 HK 1112588A1 HK 08108174 A HK08108174 A HK 08108174A HK 1112588 A1 HK1112588 A1 HK 1112588A1
Authority
HK
Hong Kong
Prior art keywords
antibody
her2
antibodies
cancer
ser
Prior art date
Application number
HK08108174.3A
Other languages
English (en)
Chinese (zh)
Other versions
HK1112588B (en
Inventor
Mika K. Derynck
Stephen M. Kelsey
Original Assignee
健泰科生物技术公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36699124&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1112588(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 健泰科生物技术公司 filed Critical 健泰科生物技术公司
Publication of HK1112588A1 publication Critical patent/HK1112588A1/xx
Publication of HK1112588B publication Critical patent/HK1112588B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069Reproductive system, e.g. ovaria, uterus, testes, prostate
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK08108174.3A 2005-02-23 2006-02-21 Extending time to disease progression or survival in cancer patients using a her dimerization inhibitor HK1112588B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65527705P 2005-02-23 2005-02-23
US60/655,277 2005-02-23
PCT/US2006/006334 WO2006091693A2 (en) 2005-02-23 2006-02-21 Extending time to disease progression or survival in cancer patients using a her dimerization inhibitor

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
HK14100881.6A Division HK1187814A (en) 2005-02-23 2008-07-24 Extending time to disease progression or survival in cancer patients using a her dimerization inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
HK14100881.6A Addition HK1187814A (en) 2005-02-23 2008-07-24 Extending time to disease progression or survival in cancer patients using a her dimerization inhibitor

Publications (2)

Publication Number Publication Date
HK1112588A1 true HK1112588A1 (en) 2008-09-12
HK1112588B HK1112588B (en) 2014-02-14

Family

ID=

Also Published As

Publication number Publication date
EP1850874B1 (en) 2013-10-16
CA2596133C (en) 2016-11-15
IL214332A0 (en) 2011-09-27
CN101163503A (zh) 2008-04-16
BRPI0606542A2 (pt) 2009-06-30
AU2006216732B2 (en) 2011-03-10
JP2017105822A (ja) 2017-06-15
IL184884A0 (en) 2007-12-03
ZA200707078B (en) 2008-11-26
TWI435730B (zh) 2014-05-01
CN101163503B (zh) 2013-05-08
JP2018135369A (ja) 2018-08-30
AU2006216732A1 (en) 2006-08-31
PL1850874T3 (pl) 2014-03-31
DK1850874T3 (da) 2013-11-11
UA95902C2 (ru) 2011-09-26
US8691232B2 (en) 2014-04-08
JP2019214601A (ja) 2019-12-19
US20090155259A1 (en) 2009-06-18
HRP20131235T1 (hr) 2014-02-14
DOP2006000052A (es) 2006-08-31
WO2006091693A3 (en) 2006-10-19
US20110165157A1 (en) 2011-07-07
NZ590431A (en) 2012-08-31
TW201402145A (zh) 2014-01-16
CL2015000428A1 (es) 2015-04-24
MX2007009889A (es) 2007-09-07
MA29331B1 (fr) 2008-03-03
AR054426A1 (es) 2007-06-27
TW200640488A (en) 2006-12-01
EP1850874A2 (en) 2007-11-07
CN103251946A (zh) 2013-08-21
RU2007135185A (ru) 2009-03-27
KR20070110298A (ko) 2007-11-16
JP2014240414A (ja) 2014-12-25
US20140186347A1 (en) 2014-07-03
KR101253576B1 (ko) 2013-04-11
GT200600092A (es) 2006-10-02
US20180236072A1 (en) 2018-08-23
WO2006091693A2 (en) 2006-08-31
PT1850874E (pt) 2013-12-02
RS53128B (en) 2014-06-30
US20150273059A1 (en) 2015-10-01
ES2440481T3 (es) 2014-01-29
CA2596133A1 (en) 2006-08-31
JP2008531576A (ja) 2008-08-14
AU2006216732C1 (en) 2017-07-20
US20060188509A1 (en) 2006-08-24
MY152164A (en) 2014-08-15
EP2399605A1 (en) 2011-12-28
JP2012211173A (ja) 2012-11-01
EP3195879A1 (en) 2017-07-26
CR9312A (es) 2008-07-31
NO20074824L (no) 2007-11-21
RU2404806C2 (ru) 2010-11-27
SI1850874T1 (sl) 2014-01-31
IL184884A (en) 2011-08-31
BRPI0606542A8 (pt) 2018-03-20

Similar Documents

Publication Publication Date Title
CN101163503B (zh) 使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活
KR20090019890A (ko) Egf 또는 tgf-알파 수준이 상승된 암 환자의 생존 연장
WO2006096861A2 (en) METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
HK1112588B (en) Extending time to disease progression or survival in cancer patients using a her dimerization inhibitor
HK1187814A (en) Extending time to disease progression or survival in cancer patients using a her dimerization inhibitor
HK1113499A (en) Selecting patients for therapy with a her inhibitor
AU2011202479A1 (en) Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor
HK1141586B (en) Predicting response to a her dimerisation inhibitor based on low her3 expression
HK1141586A1 (en) Predicting response to a her dimerisation inhibitor based on low her3 expression
HK1165303A (en) Extending time to disease progression or survival in cancer patients
HK1102770A (en) Therapy of platinum-resistant cancer
HK1102599A1 (en) Her2 antibody composition
HK1102599B (en) Her2 antibody composition